Sanofi : Is the distribution phase coming to an end ?
| Entry price | Target | Stop-loss | Potential |
|---|
|
EUR 81.11 |
EUR 88 |
EUR 77 |
+8.49% |
|---|
From a horizontal accumulation phase, the timing seems good to buy shares in Sanofi and to get ahead of a break-out on the upside of the congestion area.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● According to MSCI, the company's ESG score for its industry is good.
● Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
● The company is one of the best yield companies with high dividend expectations.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● Most analysts recommend that the stock should be sold or reduced.
● Over the past four months, analysts' average price target has been revised downwards significantly.
● The average consensus view of analysts covering the stock has deteriorated over the past four months.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
© MarketScreener.com -
2026
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener Australia. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
